Carisoprodol: uses, dosing, side effects & brands
Carisoprodol is a muscle relaxant sold in the U.S. under 2 brand and generic names, for muscle cramp, muscle rigidity and muscle spasticity. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Muscle Relaxant
- Treats
- Muscle Cramp, Muscle Rigidity and Muscle Spasticity
- Available as
- Tablet
- Sold as
- 2 products — Carisoprodol and Soma
- Prescription?
- Prescription only
- Generic available?
- Yes
- Half-life
- about 2 hours
- What the pharmacy pays
- about $2 for a 30-count supply — not your price
How carisoprodol is dosed
From the FDA label for Carisoprodol (application ANDA211789). Other carisoprodol products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The recommended dose of Carisoprodol Tablets is 250 mg to 350 mg three times a day and at bedtime. The recommended maximum duration of Carisoprodol Tablets use is up to two or three weeks. Recommended dose is 250 mg to 350 mg three times a day and at bedtime. (2)
Carisoprodol side effects
Most common adverse reactions (incidence > 2%) are drowsiness, dizziness, and headache (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Granulation Technology, Inc. at 1-973-276-0740 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in practice. The data described below are based on 1387 patients pooled from two double blind, randomized, multicenter, placebo controlled, one-week trials in adult patients with acute, mechanical, lower back pain [see Clinical Studies (14)]. In these studies, patients were treated with 250 mg of Carisoprodol, 350 mg of Carisoprodol, or placebo three times a day and at bedtime for seven days. The mean age was about 41 years old with 54% females and 46% males and 74 % Caucasian, 16 % Black, 9% Asian, and 2% other. There were no deaths and there were no serious adverse reactions in these two trials. In these two studies, 2.7%, 2%, and 5.4%, of patients treated with placebo, 250 mg of Carisoprodol, and 350 mg of Carisoprodol, respectively, discontinued due to adverse events; and 0.5%, 0.5%, and 1.8% of patients treated with placebo, 250 mg of Carisoprodol, and 350 mg of…
Who shouldn’t take carisoprodol
Carisoprodol Tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. Acute intermittent porphyria (4) Hypersensitivity reactions to a carbamate such as meprobamate (4)
Carisoprodol drug interactions
CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) - additive sedative effects ( 5.1, 7.1 ) 7.1 CNS Depressants The sedative effects of Carisoprodoland other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of Carisoprodol and Meprobamate, a metabolite of Carisoprodol, is not recommended [ see Warnings and Precautions (5.1) ]. 7.2 CYP2C19 Inhibitors and Inducers Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate [ see Clinical Pharmacology (12.3) ]. Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with Carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John’s Wort, with Carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect on CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of Carisoprodol is unknown.
Every carisoprodol product we track (2)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Tablet | Generic | $2 | View → | |
| 2 | Not yet rated | Prescription | Tablet | Generic | $2 | View → |
What carisoprodol pills look like
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
Combination products containing carisoprodol
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
How long carisoprodol keeps
No carisoprodol label we read sets a separate limit for after opening, but they do specify how it must be stored — and the stability behind any date assumes those conditions.
Does carisoprodol expire? The in-use limits and storage rules from its labelsCarisoprodol and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for carisoprodol: levels in milk, effects in breastfed infants, and the drugs it would consider insteadIf carisoprodol is required by the mother, it is not necessarily a reason to discontinue breastfeeding. Slight sedation has occurred in a breastfed newborn infant who was exposed during pregnancy and lactation; sedation might be more pronounced in newborns who are exposed for the first time during nursing. Other agents may be preferred, especially while nursing a newborn or preterm infant, or when other drugs that can cause sedation are used simultaneously.
National Institute of Child Health and Human Development, record revised November 15, 2024. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about carisoprodol
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 10,095 reports naming carisoprodol, and the FDA flagged 79% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- respiratory arrest649 reports
- chronic kidney disease551 reports
- nausea446 reports
- cardio-respiratory arrest428 reports
- headache397 reports
- depression385 reports
- acute kidney injury371 reports
- anxiety365 reports
Read these as a signal, not a rate. A report does not mean carisoprodol caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved August 25, 2026.
How long carisoprodol stays in your system
The elimination half-life of carisoprodol is about 2 hours. The label reports a terminal elimination half-life of about 2 hours for carisoprodol itself (1.7 ± 0.5 hours after a 250 mg dose, 2.0 ± 0.5 hours after 350 mg, in 24 healthy adults). But carisoprodol is converted by liver CYP2C19 into meprobamate, an active metabolite with sedative and anxiolytic properties and a half-life of about 10 hours — roughly five times longer than the parent drug, so sedation can outlast carisoprodol itself. People who are CYP2C19 poor metabolizers (about 3-5% of white and Black Americans, 15-20% of people of Asian descent) have about 4-fold higher carisoprodol exposure and about 50% lower meprobamate exposure; the label says to use carisoprodol with caution in them. Exposure to carisoprodol is also about 30-50% higher in women than men on a weight-adjusted basis. The label does not give half-life numbers for kidney or liver impairment, and states that pharmacokinetics in adults over 65 have not been established — so the ~2-hour figure is for healthy adults only. There is no extended-release carisoprodol: all US products are immediate-release tablets (250 mg and 350 mg).
Carisoprodol Tablets, 350 mg — FDA Prescribing Information, Section 12.3 Pharmacokinetics (DailyMed SPL, Oxford Pharmaceuticals, updated Dec 2024) ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Related guides
Related calculators
Frequently asked questions
What is carisoprodol?
Carisoprodol is a muscle relaxant used to treat Muscle Cramp, Muscle Rigidity, Muscle Spasticity, Myositis.
What kind of drug is carisoprodol?
The FDA classifies carisoprodol as a muscle relaxant. Most muscle relaxants work in the brain and spinal cord rather than on the muscle itself: they damp down the overactive nerve signals and reflexes that keep muscles tense, easing spasms and tightness. Some specialized agents instead act directly on muscle calcium release. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
How long does carisoprodol stay in your system?
The elimination half-life of carisoprodol is about 2 hours — that is how long the body takes to clear half of a dose. The label reports a terminal elimination half-life of about 2 hours for carisoprodol itself (1.7 ± 0.5 hours after a 250 mg dose, 2.0 ± 0.5 hours after 350 mg, in 24 healthy adults). But carisoprodol is converted by liver CYP2C19 into meprobamate, an active metabolite with sedative and anxiolytic properties and a half-life of about 10 hours — roughly five times longer than the parent drug, so sedation can outlast carisoprodol itself. People who are CYP2C19 poor metabolizers (about 3-5% of white and Black Americans, 15-20% of people of Asian descent) have about 4-fold higher carisoprodol exposure and about 50% lower meprobamate exposure; the label says to use carisoprodol with caution in them. Exposure to carisoprodol is also about 30-50% higher in women than men on a weight-adjusted basis. The label does not give half-life numbers for kidney or liver impairment, and states that pharmacokinetics in adults over 65 have not been established — so the ~2-hour figure is for healthy adults only. There is no extended-release carisoprodol: all US products are immediate-release tablets (250 mg and 350 mg). Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.
Can you take carisoprodol with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run carisoprodol against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is carisoprodol sold under?
We track 2 carisoprodol-containing products in the U.S.: Carisoprodol and Soma. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does carisoprodol come in?
Across the brands we track, carisoprodol is currently marketed as tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic carisoprodol?
Yes. Our catalog lists 1 generic carisoprodol product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.
How long does carisoprodol (Soma) stay in your system?
Carisoprodol itself is short-acting, with a half-life of about 2 hours, but it is metabolized to meprobamate, an active controlled substance with a longer half-life of roughly 10 hours (FDA label). Because of the meprobamate metabolite, carisoprodol is typically detectable in urine for about 2–4 days after use, and sometimes longer with heavy or repeated dosing. Blood windows are shorter, usually under a day for the parent drug. These ranges are approximate and depend on dose, frequency, age, and liver/kidney function. This is general information, not medical or legal advice.
Does carisoprodol appear on a standard drug test?
No, not on routine panels. Carisoprodol and meprobamate are not included in typical 5- or 10-panel workplace drug screens and do not reliably trigger a benzodiazepine or barbiturate immunoassay. Detecting them requires a specific test for carisoprodol and meprobamate, usually by GC-MS or LC-MS/MS, which labs such as Mayo, Quest, and LabCorp offer. If you have a prescription and expect targeted testing, tell the lab or medical review officer in advance. Detection depends on the assay used; this is not medical or legal advice.
Cite this page
- APA
- pharmaranks. (2026, July 24). Carisoprodol: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/carisoprodol
- MLA
- “Carisoprodol: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/carisoprodol.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for carisoprodol on DailyMed (NIH) ↗.